Cytogen (CYTO) is up over 30% on news of recognition for ProstaScint.
At noon, ~8 3/8 on over 3.6M volume.
Has there been any mention on CNBC?
----------------------------------------
cytogen.com
CYTOGEN'S PROSTATE CANCER IMAGING AGENT USED TO GENERATE NUCLEAR MEDICINE'S 'IMAGE OF THE YEAR'
- ProstaScint-guided CT scanning to aid in tumor localization within prostate gland -
PRINCETON, N.J. - June 6, 2000 - A computer-generated, three-dimensional image of the prostate gland has the potential to improve the accuracy of prostate cancer diagnosis and to aid physicians and patients in their choice of treatment options.
Cytogen Corporation's (Nasdaq: CYTO - news) ProstaScint© radio-labeled monoclonal antibody is currently marketed to produce two-dimensional images using SPECT (single photo emission computed tomography) to help physicians determine whether prostate cancer has spread beyond the gland and metastasized to others tissues.
Now, D. Bruce Sodee, M.D., Associate Professor of Radiology and Zhenghong Lee, Ph.D., Assistant Professor of Radiology, both of University Hospitals of Cleveland, Case Western Reserve University, have combined CT scans (computed tomography) with SPECT into a single, rotating, 3-D image of the diseased prostate gland.
CT scans show anatomical structures and SPECT scans, in this application, show binding of ProstaScint to a proprietary marker (prostate specific membrane antigen) on prostate cancer cells. When fused together, these images show a significantly clearer view of the tumor's size and exact location, reported Dr. Sodee at the Society of Nuclear Medicine's 47th Annual Meeting in St. Louis, Mo, this week The combined prostate scan was awarded "Image of the Year" by Society Chairman, Henry Wagner, M.D.
The rotating prostate image can be viewed by following the link to Cytogen's web site: www.cytogen.com/prostateimage.html .
"Accurately diagnosing and staging prostate cancers has the potential to change the treatment for millions of men - saving many from surgery and providing others with the most effective treatment to save or prolong their lives," said Dr. Sodee.
"This award-winning three-dimensional image underscores the potential of ProstaScint to identify cancer within the prostate gland," said Nicholas Borys, M.D., Cytogen's Vice President of Medical Affairs.
"ProstaScint is currently marketed as an imaging agent for locating metastatic prostate tumors - those that have spread beyond the gland to other sites in the body. We are supporting additional research to validate further this promising new diagnostic approach for imaging prostate cancer at its earlier stages, within the gland. Even with a needle biopsy, it can be difficult to determine the extent of cancer within the prostate. By using this non-invasive, imaging technique to locate the tumor more precisely, therapy can be individualized to each patient by placing additional radioactive seeds - so called brachytherapy - in areas of high ProstaScint uptake, while at the same time decreasing the dose to normal structures. We believe that physicians should also be able to apply direct external beam radiation more accurately to the malignant portion of the gland."
"The combined use of CT scans and ProstaScint images represents an important new marketing opportunity for our product," said Terry Novak, Cytogen's Vice President of Sales and Marketing. "We believe that this technology may reduce the number of biopsies required to accurately diagnose and stage the disease." |
